We serve Chemical Name:1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea CAS:708221-39-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea](https://a.dearchem.com/CAS2/708221-39-0.png)
Chemical Name:1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea
CAS.NO:708221-39-0
Synonyms:1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea
Molecular Formula:C18H15Cl2N5O2
Molecular Weight:404.25000
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:88.91000
Exact Mass:403.06000
LogP:4.62580
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea Use and application,1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea technical grade,usp/ep/jp grade.
Related News: The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday. 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea manufacturer Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said. 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea supplier The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea vendor The U.S. laws governing cosmetics safety and labelling date back to 1938 and 1967, which tells you something,” Bruton said.
However, on Tuesday, Sens. Susan Collins (R-Maine) and Richard Blumenthal (D-Conn.) introduced the No PFAS in Cosmetics Act in the Senate, the Washington Post reported. The same bill was introduced in the U.S. House by Rep. Debbie Dingell (D-Michigan). It would direct the U.S. Food and Drug Administration to issue a proposed rule banning the intentional addition of PFAS in cosmetics within 270 days of the bill’s passage, and require a final rule to be issued 90 days later.
“Our bill would require the FDA to ban the addition of PFAS to cosmetics products,” Collins said in a statement. “Americans should be able to trust that the products they are applying to their hair or skin are safe. 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea factory A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns.
However, on Tuesday, Sens. Susan Collins (R-Maine) and Richard Blumenthal (D-Conn.) introduced the No PFAS in Cosmetics Act in the Senate, the Washington Post reported. The same bill was introduced in the U.S. House by Rep. Debbie Dingell (D-Michigan). It would direct the U.S. Food and Drug Administration to issue a proposed rule banning the intentional addition of PFAS in cosmetics within 270 days of the bill’s passage, and require a final rule to be issued 90 days later.
“Our bill would require the FDA to ban the addition of PFAS to cosmetics products,” Collins said in a statement. “Americans should be able to trust that the products they are applying to their hair or skin are safe. 1-(3-acetylphenyl)-3-[1-[(3,4-dichlorophenyl)methyl]-1,2,4-triazol-3-yl]urea factory A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns.
